Oesophageal cancer is undergoing a therapeutic revolution, with first-generation immunotherapy trial results reading out in the next 12 months, and second-generation bispecific agents beginning evaluation alongside new targeted agents for Claudin 18.2, Her2, and FGFR.
Read more